10-valent Pneumococcal Conjugate Vaccine
Trade name: Pneumosil
Pneumococcal conjugate vaccine is a pneumococcal vaccine made with the conjugate vaccine method and used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children. — Wikipedia
Clinical trial activity
31 trials · 25 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2006 (NCT00345358)
Timeline
Indications
Approved for
Studied for
- Bacterial Infections · Phase 3
- Cough · Phase 4
- Diphtheria · Phase 3
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 2
- Fever · Phase 4
- Haemophilus influenzae type b · Phase 3
- Hepatitis B · Phase 2
- Immunization · Phase 4
- Malaria · Phase 3
- Malaria Vaccines · Phase 3
- Meningitis · Phase 3
- Meningococcal Infections · Phase 3
- Otitis Media · Phase 4
- Pertussis Vaccine · Phase 3
- Pneumococcal Infections · Phase 4
- Pneumonia · Phase 4
- Pneumonia, Pneumococcal · Phase 4
- Pneumonia, Staphylococcal · Phase 3
- Poliomyelitis · Phase 3
- Respiratory Syncytial Virus Infections · Phase 1
- Respiratory Tract Infections · Phase 4
- Rotavirus Infections · Phase 3
- Sepsis · Phase 3
- Streptococcal Infections · Phase 3
- Tetanus · Phase 3
- Vaccination · Phase 4
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPneumococcal conjugate vaccine ↗
Also known as
- phid-cv vaccine
- pneumosil
- siilpcv10
- synflorix
- synflorix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06879327 | Phase 2 | May 30, 2025 | PATH, Pharmassist Ltd |
| NCT05140720 | N/A | Jan 25, 2022 | Vabiotech, Vietnam Military Medical University, Vietstar Biomedical Research |
| NCT05175014 | Phase 4 | Dec 30, 2021 | Epicentre, Kenya Medical Research Institute, University of London |
| NCT03896477 | Phase 3 | May 31, 2019 | Institute Tropical Medicine Belgium and MRC Unit in The Gambia, PATH |
| NCT03636906 | Phase 1 | Apr 1, 2019 | GlaxoSmithKline |
| NCT03489018 | Phase 4 | Mar 30, 2019 | Bill and Melinda Gates Foundation, University of London, Wellcome Trust |
| NCT03547271 | Phase 3 | Nov 30, 2018 | Sanofi-Aventis |
| NCT02918708 | Phase 4 | Jul 1, 2017 | National Institutes of Health (NIH), Public Health England, University of London |
| NCT03197376 | Phase 3 | Jun 21, 2017 | Medical Research Council, The Gambia, PATH |
| NCT02961231 | Phase 4 | Nov 1, 2016 | Government of Vietnam, Murdoch University, University of London, University of Nagasaki |
| NCT02308540 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Medical Research Council, The Gambia, PATH |
| NCT01746108 | Phase 3 | Jun 1, 2013 | GlaxoSmithKline |
| NCT01735084 | Phase 4 | Dec 1, 2012 | Menzies School of Health Research, National Health and Medical Research Council, Australia |
| NCT01641133 | Phase 3 | Sep 1, 2012 | GlaxoSmithKline |
| NCT01616459 | Phase 2 | Jul 1, 2012 | GlaxoSmithKline |
| NCT01340898 | Phase 3 | Jan 1, 2012 | GlaxoSmithKline |
| NCT01485406 | Phase 1 | Dec 12, 2011 | GlaxoSmithKline |
| NCT01345240 | Phase 3 | Nov 1, 2011 | GlaxoSmithKline |
| NCT01619462 | Phase 3 | Nov 1, 2011 | Papua New Guinea Institute of Medical Research, Telethon Institute for Child Health Research, University of Western Australia |
| NCT01174849 | Phase 4 | Aug 1, 2011 | Menzies School of Health Research |